CLINICAL_TRIALS
trial_result
· 2016-07-07
Clinical Trial Update: Cabozantinib for Metastatic Triple Negative BrCa [Phase 2]
Summary
A Phase 2 study of cabozantinib in metastatic triple-negative breast cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-07-07